Vertex Reports meta-analysis Data for Atezolizumab in Renal cell carcinoma

Vertex today announced meta-analysis results for atezolizumab in patients with renal cell carcinoma. The study demonstrated that atezolizumab reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of renal cell carcinoma and support the continued development of atezolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.